What NWBO says they are doing, delaying the release of TLD until the full data set is ready to be published in a journal, is unprecedented for a biotech.
The strategy is very confusing to me, but I don't have the information that NWBO's management does, so who knows...maybe it will end up working out for the best.
At this point, what I care about is that the delay in releasing TLD has not slowed down the BLA application. I am very concerned that they have not really started that process, as their operating expenses over the last couple quarters don't suggest to me that they are doing much, especially if they are working on Sawston. However, they appear to be paying some consultants with stock options, so maybe that's where the BLA-related expenses are buried.
I do believe they have an approvable drug. But I'm very uncertain as to what the market size for the drug ultimately will be and the timeline for commercialization.
News 
Market Data 
Discover 
AI
